In advanced measurable soft tissue sarcoma, a randomized study of doxorubicin versus epirubicin was performed, using a dosage of 75 mg/m2 for both. The trial was conducted on a cross-over basis; if the patients progressed on doxorubicin they were crossed over to epirubicin and vice versa. There were 75 evaluable patients in each group, aged 15-18 years, all with a performance status of not less than 50. Detailed figures of the results are given. Comparing the two groups, the complete v. partial remission rates were not statistically significant. The overall response rate for doxorubicin-treated patients was slightly higher than that for those treated with epirubicin. Duration of response was about the same in each group and the survival time for the two groups was equal. Haematological toxicity, nausea and alopecia were greater with doxorubicin than with epirubicin. There were insufficient data to study the cardiotoxicity. It is concluded that doxorubicin remains the anthracycline of first choice for the treatment of soft tissue sarcomas and that in future comparisons of doxorubicin with epirubicin they should be given at haematological equitoxic doses.
|Original language||English (US)|
|Number of pages||11|
|Journal||Clinical Trials Journal|
|Issue number||SUPPL. 1|
|State||Published - 1987|
ASJC Scopus subject areas
- Pharmacology (medical)